This is a demo store. No orders will be fulfilled.
Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
13 Sep 2021  |  North America  |  Mega Trends
Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Growth Opportunities
Emerging Pharmaceuticals and Highly Potent Complex Molecules Creating Future Growth Potential
This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global small molecule contract development and manufacturing organization (CDMO) industry. It highlights key growth opportunities for small molecule CDMOs based on the main evolution in their business models and strategic approaches as well as those of...
$4,950.00 -
27 Aug 2021  |  North America  |  Mega Trends
US and EU Upstream Bioprocessing Growth Opportunities
Increasing Demand for Consumables and Single-use Technologies to Drive Growth in Upstream Bioprocessing
The Transformational Health team at Frost & Sullivan provides critical insights into the US and EU upstream bioprocessing market, highlighting drug demand trends, installed capacity developments, market revenue forecast by various segments, competitive landscape, and key growth opportunities that currently exist or are set to develop during the for...
$4,950.00 -
17 Jun 2021  |  North America  |  Mega Trends
Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities
Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential
This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as...
$4,950.00 -
13 May 2021  |  Global  |  Mega Trends
Post-COVID-19 Trends Disrupt the Global Contract Research Organization (CRO) Market
Increased Focus on Patient Centricity and Diversity in Clinical Trials Provide Growth Opportunities for CROs and Technology Vendors
Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the markets maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs, a...
$4,950.00 -
05 Feb 2021  |  North America  |  Mega Trends
Shifting Spotlight from Product- to Value-based Outcomes Intensifies Growth in the US Real-world Evidence IT Solutions Market
Early-stage R&D and Commercial Applications Fuel the Growth Pipeline
The US healthcare industrys transition to a patient-centric model is moving rapidly with focus on outcomes and value; however, drug prices have increased and pharmaceutical research and development (R&D) productivity is at its lowest. The healthcare industry and IT solutions providers are finding real-world evidence (RWE) as a potential solution to...
$4,950.00